Research programme: renin inhibitors 1100 series - SpeedelAlternative Names: SPP 1193; SPP-1100
Latest Information Update: 14 Jul 2010
At a glance
- Originator Speedel Group
- Developer Speedel
- Mechanism of Action Renin inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Hypertension
Most Recent Events
- 14 Jul 2010 Discontinued - Preclinical for Hypertension in USA (PO)
- 10 Jul 2008 Speedel Group has been acquired by Novartis